Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
22.87
-0.59 (-2.51%)
Jan 15, 2026, 12:28 PM EST - Market open
Lyell Immunopharma Market Cap
Lyell Immunopharma has a market cap or net worth of $485.85 million as of January 15, 2026. Its market cap has increased by 155.84% in one year.
Market Cap
485.85M
Enterprise Value
223.04M
1-Year Change
155.84%
Ranking
Category
Stock Price
$22.87
Market Cap Chart
Since the IPO on June 17, 2021, Lyell Immunopharma's market cap has decreased from $4.13B to $485.85M, a decrease of -88.23%. That is a compound annual growth rate of -37.32%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 14, 2026 | 498.38M | -23.78% |
| Dec 31, 2025 | 653.89M | 249.70% |
| Dec 31, 2024 | 186.98M | -61.73% |
| Dec 29, 2023 | 488.63M | -43.52% |
| Dec 30, 2022 | 865.16M | -53.52% |
| Dec 31, 2021 | 1.86B | -54.91% |
| Jun 17, 2021 | 4.13B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 961.00B |
| Johnson & Johnson | 526.55B |
| AbbVie | 392.16B |
| UnitedHealth Group | 303.42B |
| AstraZeneca | 299.25B |
| Novartis AG | 278.73B |
| Merck & Co. | 275.53B |
| Novo Nordisk | 262.20B |